SerImmune is developing an immune mapping technology that uses next-generation sequencing to identify how circulating antibodies pair with antigens.
In 86 pretreated cancer patients with mismatch repair deficiency, researchers saw objective response rates exceeding 50 percent after anti-PD-1 immunotherapy.
The researchers plan to profile patients with both Adaptive Biotechnologies' ImmunoSeq platform and 10x Genomics' single-cell immune repertoire profiling technology.
Illumina's partnership with the Human Vaccines Project and Vanderbilt looks to crunch data sets billions of times larger than human genome.
The project aims to sequence the immune repertoires of study participants to spur new vaccine and immunotherapy development.
Adaptive aims to commercialize and scale its techniques to identify immune signatures in other infectious diseases, autoimmune disorders, and even cancer.
The single-cell VDJ profiling kit is the first of a suite of immunology products the company plans to launch this year.
The partners will characterize patient immune response to two new investigational immunotherapies from Argos Therapeutics.
The technique could be commercialized and used to understand immune response to viruses and cancer in order to develop immunotherapies.
The company is using its MIRA assay internally and in research collaborations to identify biomarkers that can serve as the basis for immunotherapies.
A genetic genealogy analysis helped secure the release of a California man from prison after getting his murder conviction overturned, the Guardian reports.
Technology Review discusses the concerns that come along with the ability to quickly synthesize viruses like SARS-CoV-2.
Researchers have uncovered large bacteriophages whose genomes include translational machinery, Live Science reports.
In PNAS this week: role for Myc in alternative splicing regulation in prostate cancer, variation in methylation in Arabidopsis, and more.